Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Andrx Divests Oral Contraceptive ANDAs To Teva

This article was originally published in The Pink Sheet Daily

Executive Summary

Under merger agreement with Watson. Andrx will divest ANDAs of competing products to marketing partner Teva.

You may also be interested in...



FTC Clearance Of Watson’s Andrx Acquisition Requires 13 Generic Divestitures

Proposed consent decree calls for Watson/Andrx to sell marketing rights for generic Glucotrol XL and generic Vicoprofen.

FTC Clearance Of Watson’s Andrx Acquisition Requires 13 Generic Divestitures

Proposed consent decree calls for Watson/Andrx to sell marketing rights for generic Glucotrol XL and generic Vicoprofen.

Teva Will Inherit OAI Status Of Andrx' Oral Contraceptives

FDA will continue to block approval of Andrx' oral contraceptives until manufacturing issues are resolved despite the company's intention to transfer its pending ANDAs to Teva

Related Content

Topics

UsernamePublicRestriction

Register

LL016481

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel